Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03711292
Other study ID # 31429-01
Secondary ID UL1TR001881
Status Completed
Phase N/A
First received
Last updated
Start date September 7, 2018
Est. completion date August 31, 2021

Study information

Verified date October 2018
Source Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Stepped wedge behavioral intervention clinical trial looking at the impact of an antibiotic stewardship intervention on provider prescribing behavior for acute respiratory infections (ARIs), where the intervention is administered at the emergency department or urgent care center site level, using a cluster randomization process. Thus, every site and every provider are eligible to be exposed to the stewardship intervention, the cluster randomized stepped wedge process simply randomizes when they will be exposed. The overall study hypothesis is that providers will prescribe fewer unnecessary antibiotics to patients with ARIs after the intervention.


Description:

Hypothesis: The primary hypothesis is that acute care ambulatory settings randomized to receive behavioral economic stewardship interventions will have decreased antibiotic prescribing rates for non-antibiotic appropriate ARIs, compared to contemporaneous antibiotic prescribing rates for non-antibiotic appropriate ARIs among control practices. This hypothesis will be evaluated in a linear mixed effects model will be used to estimate and test the group effect using group and time as fixed effects and practice site and provider as random effects. The interaction between time and group will be included to estimate and test the different group effect over time. Design: The investigators will conduct a stepped wedge cluster randomized trial of acute care ambulatory visits to emergency departments and urgent care centers in a predominantly non-academic public hospital system. Clustering (by site) helps prevent treatment contamination between individual clinicians within the same site. The stepped wedge design will allow studying the effects of a complex intervention rolled out through a system over time, as often happens in the real-world, where State and Federal public health as well as site-based organization quality improvement interventions may be occurring at different times. Treatment Assignment Procedures: For the 12-month intervention period, in a stepped-wedge fashion, sites will be exposed to a site-adapted multifaceted stewardship intervention consistent with Centers for Disease Control and Prevention (CDC) core elements for outpatient antimicrobial stewardship: commitment, action, monitoring, reporting and education, and also included a behavioral component that used individualized audit and feedback, peer comparison, and public commitment, in addition to standard patient and clinician education on antibiotic prescribing for antibiotic nonresponsive ARIs.


Recruitment information / eligibility

Status Completed
Enrollment 134
Est. completion date August 31, 2021
Est. primary completion date February 28, 2021
Accepts healthy volunteers No
Gender All
Age group 21 Years and older
Eligibility The primary research subjects involved in this trial are prescribing providers who will be recruited from multiple clinical sites in Los Angeles County Department of Health Services. Eligibility (provider) Inclusion Criteria: * Prescribing provider in an adult emergency department or urgent care center in the Los Angeles County Department of Health Services. Exclusion Criteria: * Provider has not treated a patient with an ARI Eligibility (patient) Inclusion Criteria: - Treated at a Los Angeles County Department of Health Services facility with an ARI diagnosis - Cared for by a provider and in practice site enrolled in the study - Visit occurred during the 12-month intervention period, or the 12-month historical baseline period - Did not have a visit with any ARI diagnosis in the prior 30 days Exclusion Criteria: * None

Study Design


Intervention

Behavioral:
Antibiotic Stewardship
For the 12-month intervention period, in a stepped-wedge fashion, sites will be exposed to a site-adapted multifaceted stewardship intervention consistent with CDC core elements for outpatient antimicrobial stewardship: commitment, action, monitoring, reporting and education, and also included a behavioral component that used individualized audit and feedback, peer comparison, and public commitment, in addition to standard patient and clinician education on antibiotic prescribing for antibiotic nonresponsive ARIs.

Locations

Country Name City State
United States Department of Health Services Los Angeles California

Sponsors (3)

Lead Sponsor Collaborator
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Los Angeles County Department of Public Health, University of California, Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Antibiotic prescribing The primary outcome measure is the rate of antibiotic prescribing for non-antibiotic-appropriate acute respiratory infections or in other words, acute respiratory infections that are presumed to be viral in nature. The International Classification of Diseases (ICD)-10 codes for primary outcomes are defined in detail in the clinical trials protocol document. These outcomes are computable clinical quality measures from the electronic health record. These are widely used in medicine to evaluate quality improvement and reliability and validity are generally supported.
Visits are excluded from the primary analysis when: 1) patients have certain medical co-morbidities that make ARI guidelines less likely to apply, 2) patients had concomitant visit diagnoses indicating a non-ARI possible bacterial infection, or 3) patients had concomitant visit diagnoses indicating potentially antibiotic appropriate ARI diagnoses or other ARI diagnoses suggestive of a bacterial infection.
12 months
Secondary Diagnostic drift Throughout the course of the study, the investigators will also be monitoring "diagnostic drift" that may result in provider shifting diagnosis to avoid guideline conflicts that might trigger poor performance reports. An auditing program will measure diagnostic deviation from each clinician's historical rates of diagnosing acute respiratory infections. 12 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT03517215 - The Development and Testing of a Scaling Strategy for a Community-Based Primary Care Antimicrobial Stewardship Program N/A
Completed NCT01420445 - Safety/Tolerability and Efficacy of YHD001 in Patients With Acute and Chronic Bronchitis Phase 2
Completed NCT00360464 - A Trial Of Azithromycin SR For The Treatment Of Acute Bronchitis And Secondary Infection Of Chronic Respiratory Diseases Phase 3
Completed NCT05344638 - A Clinical Trial to Evaluate the Safety and Efficacy of "AG1904" in Acute Bronchitis Phase 3
Completed NCT06457269 - Evaluating the Potential of Large Language Models for Respiratory Disease Consultations N/A
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Recruiting NCT03827590 - Clinical Trials to Assess the Efficacy and Safety of HLIM Phase 3
Completed NCT02792946 - Compare the Efficacy and Safety of Surfolase CR Tablet With Surfolase Capsule in Patients With Acute Bronchitis Phase 3
Completed NCT01875757 - Effect of Supplementation With Vitamin D on the Acute Bronchitis Prevention During the First Year of Life Phase 3
Recruiting NCT04252963 - Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(Streptokinase • Streptodornase) Phase 4
Recruiting NCT06411925 - The Efficacy and Safety of Atock Dry Syrup With Acute Bronchitis Patients Phase 4
Completed NCT01416480 - Clinical Trial to Evaluate the Safety and Efficacy of "Theobromine Capsule" as an Antitussive in Acute Cougher Phase 3
Enrolling by invitation NCT05916768 - Management of Acute Bronchitis With Pelargonium Sidoides Extract N/A
Completed NCT03309800 - A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Placebo in Acute Bronchitis Patients Phase 2
Completed NCT02250027 - A Multicenter, Randomized, Double-blind, Parallel Group Study to Determine the Optimal Dose of HL301 After 7 Days Oral Administration in Acute Bronchitis or Acute Exacerbations of Chronic Bronchitis Patients (HL301: Mixed Extract of Rehmannia Glutinosa, Schisandra and so on) Phase 2
Not yet recruiting NCT03310385 - Efficacy and Safety of GHX02 in the Treatment of Acute Bronchitis Phase 2
Completed NCT03654196 - A Clinical Trial to Evaluate the Efficacy and Safety of HL301 Versus Umkamin Tab in Acute Bronchitis Patients Phase 3
Completed NCT03011515 - Evaluating a Host-response Based Diagnostic for Distinguishing Between Bacterial and Viral Etiology in Patients With Lower Respiratory Tract Infection (LRTI)
Completed NCT02045394 - Epidemiology and Diagnosis of Haemoptysis: a Multicenter Study N/A
Completed NCT01800747 - Clinical Trial for the Assessment of Delayed Antibiotic Treatment in Pediatric (DAP-Pediatrics) Phase 4